




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8




FIG. 9




FIG. 10




FIG. 11





FIG. 12



Bonferroni multiple comparison test	Statistical remarks
Group 1 versus Group 2	Statistically non-significant (Day 3 to Day 13)
Group 1 versus Group 3	Statistically non-significant (Day 3 to Day 13)
Group 1 versus Group 4	Statistically non-significant (Day 3 to Day 13)

FIG. 13





FIG. 14



Bonferroni multiple comparison test		Statistical remarks
Group 2 versus Group 3		Statistically non-significant (Day 3 to Day 13)
Group 2 versus Group 4		Statistically significant on Day 11(*p<0.05)
Group 2 versus Group 5		Statistically non-significant (Day 3 to Day 13)

FIG. 15




FIG. 16




FIG. 17A




FIG. 17B




FIG. 18





FIG. 19

Material	Erdafitinib free base	Erdafitinib free base + HP- β -CD	Erdafitinib HCl salt
Silicone (MED-4750)	X	X	X
TPU (PC-3575A)	X	X	X
TPU (AR-62A)	X	X	X
TPU (HP-60D-35)	O	O	O
TPU (AC-4075A)	X	X	X
TPU (TT-1074A)	X	Δ	X
TPU (HP-93A-100)	O	O	O
TPU (EG-80A)	Δ	O	Δ
EVA (CoTran 9712)	Δ^a	X	Δ

O, permeable; Δ , practically impermeable; X, impermeable


^a High variability between replicates

FIG. 20




Erda, erdafitinib; HPβCD, hydroxypropyl β-cyclodextrin

FIG. 21



Erda, erdafitinib; HP- β -CD, hydroxypropyl β -cyclodextrin; SU, simulated urine

FIG. 22



Erda, erdafitinib; HP-β-CD or HPβCD, hydroxypropyl β-cyclodextrin; SU, simulated urine

FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28A

Base material	Stripe material	Stripe angle(s)	Wall thickness	API form	Expected max release rate (pH 5)	Expected zero-order duration	pH dependency
AR-75A-B20 or AC-4075A-B20	EG-80A	45°, 90°, 120°, 150°, 180°	0.2 mm	Free base+ HP-β-CD	1-4 mg/day	>90 days	Minimal (pH 5 and pH 6.8 agree well; pH 8~50% lower)

API, active pharmaceutical ingredient; HP-β-CD, hydroxypropyl β-cyclodextrin

FIG. 28B

Solvent	Solubility in mg per mL solution	pH of solution	Descriptive solubility ^a
Water	<0.01	7.7	Practically insoluble or insoluble
0.1N HCl	2.3	1.1	Slightly soluble
0.01N HCl	0.73	1.9	Very slightly soluble
Citric acid-NaOH-HCl buffer pH 2	0.92	1.7	Very slightly soluble
Citric acid - NaOH buffer pH 5	0.37	5.3	Very slightly soluble
Phosphate buffer pH 7	6.5	7.4	Slightly soluble
Boric acid-KCl-NaOH buffer pH 9	0.01	9.0	Practically insoluble or insoluble
Phosphate-NaOH buffer pH 12	<0.01	12.0	Practically insoluble or insoluble
0.1N NaOH	<0.01	12.9	Practically insoluble or insoluble

a USP/Ph. Eur. terminology

FIG. 29




FIG. 30A




FIG. 31A

	Sim urine (pH 5.2-5.3)	Sim urine (pH 7.0-7.2)	Sim urine (pH 8.0-8.3)
0% HP-β-CD	0.84	4.61	0.03
5% HP-β-CD	9.05	8.17	2.55
10% HP-β-CD	12.75	11.1	5.8

HP-β-CD, hydroxypropyl β-cyclodextrin; Sim urine, simulated urine.

FIG. 31B